CAR-T Cell Therapy
Hematology
Daga
$47,000
Har zuwa $200,000 ya danganta da cibiya
Tsawon lokaci na yau da kullum
20–50 days
Hada da gwaje-gwajen kafin tiyata
Asibitocin hadin gwiwa
0
An duba su don bayanan sakamako da takardar shaida
Bayyani
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary form of personalised cancer immunotherapy in which a patient's own T-cells are genetically engineered to identify and destroy cancer cells with precision. Approved for certain blood cancers — including relapsed or refractory B-cell lymphomas, acute lymphoblastic leukaemia (ALL), and multiple myeloma — CAR-T has achieved remission in patients who failed all prior therapies. China is a world leader in CAR-T innovation with domestically approved products (Relma-cel, Yescarta/Fosun Kite) at a fraction of US costs. India offers the homegrown NexCAR19 product at around $50,000 — one-tenth of the US price — through JCI-accredited centres including Christian Medical College Vellore.
Ana daidaita al'amarinku da cibiya bisa bayanan sakamako na likitanci, ba talla ba. Muna tsara kowane mataki — daga gwaje-gwajen kafin tiyata zuwa biye-biye bayan jiyya — tare da mai tsara kulawa na musamman.
Abinda ya hada
CAR-T Cell Therapy
An tsara daga
ko aiko mana sako a kan WhatsApp
Ba a bukatar alkawari. Ba a taba raba bayananku da wasu jam'iyyu ba.
Kwatancen farashi na duniya — CAR-T Cell Therapy
Matsakaicin farashi da aka tsara a fadin cibiyoyinmu na hadin gwiwa. Farashin karshe ya danganta da tsananin yanayi da asibitin da aka zaba.
| Kasa | Matsakaicin farashi | idan aka kwatanta da mafi araha |
|---|---|---|
🇮🇳 India New Delhi · Chennai · Bengaluru · Hyderabad · Mumbai · Kochi | $65,000 | —chevron_right |
🇨🇳 China Shanghai · Beijing · Hainan (Boao) | $150,000 | +131%chevron_right |
Farashi alama ce kuma ana bita su kowane kwata. Nemi kimar musamman don al'amarinku.
Tambayoyin da ake yawan yi
CAR-T is currently approved for relapsed or refractory large B-cell lymphoma (including DLBCL), follicular lymphoma, mantle cell lymphoma, B-cell acute lymphoblastic leukaemia (ALL), and multiple myeloma after prior lines of therapy. Eligibility depends on your specific cancer subtype, prior treatment history, molecular markers (e.g., CD19, BCMA expression), and performance status. Our partner centres will review your pathology reports, treatment history, and imaging to determine candidacy before you travel.
Babu kudi. Babu alkawari.
Jagoranmu kyauta ne gaba daya
Asibitocinmu na hadin gwiwa ne suke biyanmu — ba majinyata ba. Kuna samun daidaita likitanci mai zaman kansa, bayyana farashi, da cikakken tsari ba tare da kudi a kanku ba.